Geron Corporation (GERN) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 2025 Net Revenue: $48 million, consistent with expectations.

Full Year 2025 Net Revenue: $184 million, significantly up from $76 million in 2024, marking Rytelo's first full year of commercialization.

Total Operating Expenses (2025): Approximately $255 million, aligning with guidance of $250 million to $260 million.

Gross-to-Net Deductions: Increased to 17.7% in 2025 from 14.5% in 2024, attributed to wider 340B utilization and expanded GPO contracting.

Cash Position: Approximately $400 million as of December 31, 2025, down from $503 million in 2024, but with access to an additional $125 million through a loan amendment.

2Strategic Updates and Business Highlights

Geron has restructured to focus on becoming a commercially driven organization, enhancing its leadership and refining its commercial strategy.

Rytelo's growth strategy includes increasing awareness among healthcare professionals and expanding research partnerships within the hematology community.

The company is targeting approximately 8,000 second-line lower-risk MDS patients in the U.S., leveraging updated NCCN guidelines that favor Rytelo as a second-line treatment option.

3Forward Guidance and Outlook

2026 Rytelo Net Revenue Guidance: Expected between $220 million and $240 million, with growth anticipated in the latter half of the year.

2026 Total Operating Expenses Guidance: Projected to be between $230 million and $240 million, reflecting a streamlined approach.

Geron aims to maintain operational execution and patient delivery, with a focus on commercial growth and potential international expansion.

4Bad News, Challenges, or Points of Concern

The increase in gross-to-net deductions indicates potential pricing pressures as the business matures.

The company is facing competitive pressures from existing therapies, particularly ESAs and the evolving treatment landscape with luspatercept.

There is uncertainty regarding the European market, particularly concerning HTA processes and pricing negotiations, which could impact future revenue from international markets.

5Notable Q&A Insights

Management emphasized the importance of Q4's 9% demand growth as a positive indicator for future performance.

There is a clear focus on expanding both the breadth (new prescribing accounts) and depth (repeat prescriptions) of Rytelo usage.

The company sees a path to profitability but prioritizes investments in commercial strategies and clinical trials over immediate profitability.

The management acknowledged the shift in treatment paradigms, with Rytelo positioned favorably as a second-line treatment following luspatercept, which is becoming more dominant in first-line settings. Overall, Geron Corporation's Q4 2025 earnings call highlighted a year of significant revenue growth and strategic realignment, setting the stage for continued focus on Rytelo's commercialization and market penetration in 2026, despite facing competitive and operational challenges.